NCT01693640已完成早期 1 期
A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Mucocutaneous Manifestations of Behcet's Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- ulcers
研究概览
简要总结
Hypothesis: Abatacept injections will decrease the number of oral ulcers seen in Behcet's patients
详细描述
This will be an open label study, where 20 Behcet's patients with resistant oral ulcers and 10 with resistant genital ulcers will be enrolled (screen 40). After enrollment all patients will be followed for a month to document the number of oral and genital ulcers on their current regimen. Then all patients will receive abatacept for 6 months (evaluated at weeks 0, 2, 4, 8, 12, 16 and 24). Then the treatment will be stopped and they will be observed for the next 2 months, for a total of 9 month trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 10 weeks after the last dose of study drug.
- •Women who are pregnant or breastfeeding.
- •Women with a positive pregnancy test on enrollment or before administration of abatacept.
- •Target Disease Exceptions [Include as applicable]
- •Any patients with systemic manifestations of Behcet's syndrome (Patients with eye, CNS, vascular involvement, gastrointestinal disease)
- •Patients who are already on other immunosuppressive medications (azathioprine, TNF inhibitors, other biologic agents, methotrexate, mycophenolate mofetil, cyclosporine, cyclophosphamide)
- •Subjects who are impaired, incapacitated, or incapable of completing study-related assessments.
- •Subjects with current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, whether or not related to Behcet's syndrome and which, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study.
- •Female subjects who have had a breast cancer screening that is suspicious for malignancy and in whom the possibility of malignancy cannot be reasonably excluded by additional clinical, laboratory, or other diagnostic evaluations.
- •Subjects with a history of cancer in the last 5 years, other than non-melanoma skin cell cancers cured by local resection or carcinoma in situ.
- •Subjects who currently abuse drugs or alcohol.
- •Subjects with evidence (as assessed by the investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of human immunodeficiency virus (HIV) detected during screening.
- •Subjects with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months before the informed consent document was signed.
- •Subjects who have received any live vaccines within 3 months of the anticipated first dose of study medication.
- •Subjects with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection (eg, chronic pyelonephritis, osteomyelitis, or bronchiectasis).
- •Subjects at risk for tuberculosis (TB).
- •Subjects must not be positive for hepatitis B surface antigen.
- •Subjects who are positive for hepatitis C antibody if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay.
- •Subjects with any of the following laboratory values
- •Hemoglobin < 8.5 g/dL
- •WBC < 3000/mm3 (< 3 x 109/L)
- •Platelets < 100,000/mm3 (< 3 x 109/L)
- •Serum creatinine > 2 times the ULN
- •Serum ALT or AST > 2 times the ULN
- •Any other laboratory test results that, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study.
- •Subjects who have at any time received treatment with any investigational drug within 28 days (or less than 5 terminal half-lives of elimination) of the Day 1 dose.
- •Any concomitant biologic DMARD.
研究组 & 干预措施
abatacept
Experimental
干预措施: Abatacept (Drug)
结局指标
主要结局
ulcers
时间窗: 6 month treatment period
The primary endpoint is number of oral and genital ulcers (AUC) during the treatment period
次要结局
- Genital ulcers(6 month treatment)
- Treatment failures(6 months)
- Side Effects(6 months)
- Oral ulcer pain(6 months)
- MDHAQ(6 months)
- BSAS(6 months)
- BDCAF(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Uses of Tacrolimus in Behcet DiseaseOral UlcerBehcet SyndromeNCT05032248Assiut University40
已完成
2 期
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)Minimal Change DiseaseFocal Segmental GlomerulosclerosisNephrotic SyndromeNCT02592798Bristol-Myers Squibb36
已完成
2 期
Abatacept in the Treatment of UveitisUveitisNCT01279954Oregon Health and Science University10
已完成
4 期
EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)Palindromic Rheumatism, WristNCT03669367Fundacion Clinic per a la Recerca Biomédica70
撤回
不适用
Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir BackgroundChronic Hepatitis BRheumatoid ArthritisNCT02053727University of California, Los Angeles